LitAlert ~~ GeneLit.com

    • Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.
    • Ming C, Viassolo V, Probst-Hensch N, Dinov ID, Chappuis PO, Katapodi MC.
    • Br J Cancer. 2020 Jun 22. doi: 10.1038/s41416-020-0937-0. Epub ahead of print.
    • Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    • Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.
    • Clin Cancer Res. 2020 Jun 22. doi: 10.1158/1078-0432.CCR-20-0638. Epub ahead of print.
    • Genetic testing and results disclosure in diverse populations: what does it take?
    • Horowitz CR.
    • Genet Med. 2020 Jun 22. doi: 10.1038/s41436-020-0874-6. Epub ahead of print.
    • Commentary
    • MSK Researches Find High Prevalence of Germline Mutations in Patients With Early-Onset Cancers.
    • Hopkins C.
    • GenomeWeb. 2020 Jun 22.
    • UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants.
    • Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, Izatt L, Sohaib A, Tischkowitz M, Evans DG.
    • J Med Genet. 2020 Jun 22:jmedgenet-2020-106876. doi: 10.1136/jmedgenet-2020-106876. Epub ahead of print.
    • Decision-making in cancer care for people living with dementia.
    • Griffiths AW, Ashley L, Kelley R, Cowdell F, Collinson M, Mason E, Farrin A, Henry A, Inman H, Surr C.
    • Psychooncology. 2020 Jun 21. doi: 10.1002/pon.5448. Epub ahead of print.
    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • The evolving management of metastatic triple negative breast cancer.
    • Malhotra MK, Emens LA.
    • Semin Oncol. 2020 May 28:S0093-7754(20)30044-0. doi: 10.1053/j.seminoncol.2020.05.005.
    • Review